Outcomes of neoadjuvant therapy for cholangiocarcinoma: A review of existing evidence assessing treatment response and R0 resection rate
| Autor: | Victoria V O'Connor, Yuman Fong, Viet H. Le, Laleh G. Melstrom, Daneng Li, Andrew L DiFronzo |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty Treatment response Systemic disease medicine.medical_treatment Aggressive disease Cholangiocarcinoma 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Radical surgery Neoadjuvant therapy Intrahepatic Cholangiocarcinoma R0 resection business.industry General Medicine Prognosis medicine.disease Occult Neoadjuvant Therapy Bile Duct Neoplasms 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology Surgery Neoplasm Recurrence Local business |
| Zdroj: | Journal of Surgical Oncology. 123:164-171 |
| ISSN: | 1096-9098 0022-4790 |
| DOI: | 10.1002/jso.26230 |
| Popis: | Adjuvant chemotherapy for cholangiocarcinoma (CCA) has not been shown to gain significant improvements in survival. Factors contributing to suboptimal treatment response include aggressive disease biology and late clinical presentation. When feasible, surgical resection is the first line of treatment. Yet, recurrence remains high and long-term survival is rare. Neoadjuvant therapy is an appealing approach, with oncologic advantages in allowing the treatment of occult systemic disease and selection of patients most likely to benefit from radical surgery. However, given the surgery-first treatment paradigm for CCA, there is a paucity of data supporting neoadjuvant therapy. This review summarizes the current evidence on treatment response and margin-negative (R0) resection rate associated with neoadjuvant therapy for CCA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text